FGFR2 (K641R)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.K641R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 100.0% | 0.0% | 98.48 |
| 2 | Ponatinib | 99.9% | 0.1% | 78.23 |
| 3 | Selpercatinib | 99.3% | 0.7% | 96.72 |
| 4 | Alpelisib | 99.1% | 0.9% | 97.22 |
| 5 | Nintedanib | 98.6% | 1.4% | 90.23 |
| 6 | Vandetanib | 98.4% | 1.6% | 95.74 |
| 7 | Brigatinib | 97.8% | 2.2% | 82.96 |
| 8 | Erdafitinib | 97.5% | 2.5% | 95.71 |
| 9 | Axitinib | 97.1% | 2.9% | 93.23 |
| 10 | Pemigatinib | 96.2% | 3.8% | 98.23 |
| 11 | Canertinib | 96.2% | 3.8% | 96.49 |
| 12 | Erlotinib | 95.6% | 4.4% | 99.75 |
| 13 | Infigratinib | 95.1% | 4.9% | 98.24 |
| 14 | Pazopanib | 94.2% | 5.8% | 97.49 |
| 15 | Dasatinib | 93.2% | 6.8% | 87.97 |
| 16 | Pralsetinib | 93.2% | 6.8% | 93.43 |
| 17 | Pexidartinib | 92.4% | 7.6% | 99.49 |
| 18 | Fedratinib | 87.8% | 12.2% | 96.21 |
| 19 | Sunitinib | 86.9% | 13.1% | 91.73 |
| 20 | Tivozanib | 86.8% | 13.2% | 92.42 |
| 21 | Bosutinib | 83.8% | 16.2% | 87.22 |
| 22 | Dacomitinib | 82.6% | 17.4% | 97.99 |
| 23 | Lenvatinib | 81.6% | 18.4% | 97.74 |
| 24 | Pacritinib | 81.0% | 19.0% | 88.64 |
| 25 | Repotrectinib | 80.0% | 20.0% | 84.21 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 100.0% | 99.3% | +0.7% |
| Ponatinib | 99.9% | 99.4% | +0.5% |
| Selpercatinib | 99.3% | 95.0% | +4.3% |
| Alpelisib | 99.1% | 98.9% | +0.1% |
| Nintedanib | 98.6% | 97.0% | +1.6% |
| Vandetanib | 98.4% | 90.8% | +7.6% |
| Brigatinib | 97.8% | 96.1% | +1.7% |
| Erdafitinib | 97.5% | 99.0% | -1.5% |
| Axitinib | 97.1% | 96.1% | +0.9% |
| Pemigatinib | 96.2% | 98.7% | -2.5% |
| Canertinib | 96.2% | — | — |
| Erlotinib | 95.6% | — | — |
| Infigratinib | 95.1% | 98.8% | -3.7% |
| Pazopanib | 94.2% | 88.9% | +5.3% |
| Dasatinib | 93.2% | — | — |
| Pralsetinib | 93.2% | 93.2% | -0.1% |
| Pexidartinib | 92.4% | — | — |
| Fedratinib | 87.8% | — | — |
| Sunitinib | 86.9% | — | — |
| Tivozanib | 86.8% | — | — |
| Bosutinib | 83.8% | — | — |
| Dacomitinib | 82.6% | — | — |
| Lenvatinib | 81.6% | 85.4% | -3.8% |
| Pacritinib | 81.0% | — | — |
| Repotrectinib | 80.0% | 79.8% | +0.2% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_biliary_tract | Biliary Tract | ref |
| carcinoma_salivary_gland | Salivary Gland | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.6ms